Welcome to our dedicated page for Polyrizon SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. entered into definitive agreements for a registered direct offering and concurrent private placement expected to raise approximately $3.5 million in gross proceeds. The structure combines ordinary shares, low-priced pre-funded warrants, and five-year common warrants priced through units at $9.00 per unit.
The company will sell 87,777 ordinary shares and 190,000 pre-funded warrants in the registered direct deal, plus 111,111 PIPE pre-funded warrants and 388,888 common warrants in the private placement. Following completion and full exercise of all pre-funded warrants, Polyrizon expects to have 2,083,939 ordinary shares outstanding and plans to use the net proceeds for general corporate purposes and working capital.
Polyrizon Ltd. is registering 87,777 Ordinary Shares and 190,000 Pre-Funded Warrants (each exercisable for one Ordinary Share) at $9.00 per Ordinary Share and $8.99999 per Pre-Funded Warrant, respectively. The offering includes the Ordinary Shares issuable upon exercise of the Pre-Funded Warrants. Delivery is expected on or about April 8, 2026.
There is a concurrent private placement of 111,111 PIPE Pre-Funded Warrants and 388,888 unregistered Ordinary Share Warrants (exercise price $9.00; five-year term). Proceeds before expenses for the registered portion are approximately $2.499,991.10 with estimated net proceeds combined from the offering and concurrent private placement of approximately $3.1M. Ordinary Shares outstanding prior to the offering were 1,695,051, rising to 1,972,828 assuming full exercise of the Registered Pre-Funded Warrants.
Polyrizon Ltd. Chief Executive Officer Tomer Izraeli sold 500 ordinary shares in an open-market transaction at $11.85 per share. Following the sale, he directly holds 31,512 ordinary shares.
These holdings consist of 6,459 ordinary shares, 53 restricted ordinary shares that vest monthly, and 25,000 restricted ordinary shares that vest quarterly, each vesting schedule being subject to his continued service.
Polyrizon Ltd. director Carmel Liron reported an open-market sale of 942 Ordinary Shares at $12.36 per share. After this transaction, Liron directly holds 3,127 Ordinary Shares. These holdings consist of 521 ordinary shares and 2,606 restricted ordinary shares that vest in equal quarterly installments, subject to continued service.
Polyrizon Ltd. director Adler Oz reported an open-market sale of 3,292 Ordinary Shares on March 31, 2026 at a weighted average price of $12.05 per share, with individual trade prices ranging from $12.00 to $12.1041.
After this transaction, Oz holds a total of 19,850 Ordinary and restricted Ordinary Shares, consisting of 3,363 Ordinary Shares, 29 restricted Ordinary Shares that vest monthly, and 16,458 restricted Ordinary Shares that vest quarterly, all subject to continued service.
Polyrizon Ltd. director Carmel Liron reported an open-market sale of 100 Ordinary Shares of Polyrizon on March 30, 2026 at $11.00 per share. After this transaction, Liron directly holds 4,069 ordinary shares, consisting of 1,463 ordinary shares and 2,606 restricted ordinary shares that vest in equal quarterly installments, subject to continued service.
Polyrizon Ltd. Chief Executive Officer Tomer Izraeli reported an open-market sale of 3,900 Ordinary Shares on March 30, 2026 at $10.90 per share. After this transaction, he directly holds 32,012 Ordinary Shares.
According to the footnote, his holdings consist of 6,959 ordinary shares and 25,053 restricted ordinary shares. The restricted shares vest in equal installments, with 53 shares vesting monthly and 25,000 shares vesting quarterly, in each case subject to his continued service.
Polyrizon Ltd. Chief Technology Officer Tidhar Turgeman reported an open-market sale of 2,917 Ordinary Shares of PLRZ at $10.90 per share. After this transaction, he directly holds 17,518 Ordinary Shares.
According to the filing, this position includes 18 restricted ordinary shares that vest in equal monthly installments and 17,500 restricted ordinary shares that vest in equal quarterly installments, in each case subject to his continued service with the company.
Polyrizon Ltd. filed an amended Form 20-F to correct Item 15 and reaffirm that its disclosure controls and procedures were effective as of December 31, 2025. Management also concluded that internal control over financial reporting was effective under the COSO 2013 framework, with no auditor attestation required due to emerging growth company status.
The report describes a cybersecurity-related business email compromise in October 2025 that caused a wire transfer of approximately $464,000 to the wrong account, and a second attempted fraud in December 2025 that was prevented. The company reports the incident did not have a material impact but may lead to additional investigation and remediation costs, and outlines new verification and cybersecurity measures adopted in response.
Polyrizon Ltd., an Israel-based biotech company, files its annual report on Form 20-F, describing a development-stage business focused on C&C nasal barrier products and a T&T nasal drug-delivery platform. The company has not generated product revenue and is heavily dependent on successful clinical development and regulatory approvals.
Polyrizon reports operating losses of $6.249 million and $1.302 million for the years ended December 31, 2025 and 2024, with an accumulated deficit of about $8.4 million. As of December 31, 2025, it had 1,608,266 ordinary shares outstanding, cash and cash equivalents of $1.3 million and bank deposits of $16.2 million.
The report highlights significant risks, including the expectation of continued losses, the need for substantial additional funding, dependence on patient enrollment and regulatory clearances in the United States and European Union, and heavy reliance on its novel C&C and T&T technologies. Polyrizon is an emerging growth company and foreign private issuer, using reduced reporting and extended transition periods for new accounting standards, which may make comparisons to other public companies more difficult.